Buprenorphine — Suboxone (combined with naloxone), Sublocade (LAI), Zubsolv — is the gold standard for opioid use disorder pharmacotherapy in most modern practice. The mechanism is partial mu opioid agonism, and that partial agonism is what makes buprenorphine work where methadone, naltrexone, and abstinence-only approaches often don't.
- Class
- Partial mu opioid receptor agonist
- Mechanism
- High-affinity partial mu agonist + kappa antagonist. Provides opioid effect strong enough to prevent withdrawal but with ceiling effect (lower overdose risk than full agonists). Displaces other opioids from receptors.
- Typical dose
- 8-24 mg/day sublingual (Suboxone with naloxone, Zubsolv, generic); LAI Sublocade 100-300 mg monthly SC
- Half-life
- ~24-37 hours
- FDA indications
- Opioid use disorder, opioid dependence treatment, chronic pain (specific formulations)
- Key adverse effects
- Constipation, sweating, sedation, nausea early. Precipitated withdrawal if used too soon after full agonist. Lower respiratory depression than full agonists (ceiling effect) — but combination with benzodiazepines can still produce respiratory depression.
Black box: Concomitant benzodiazepine/CNS depressant use; neonatal abstinence syndrome if used in pregnancy
Gold standard for OUD. Outpatient initiation possible (vs. methadone clinic requirement). Suboxone combines with naloxone for abuse deterrence (naloxone inactive sublingual, prevents IV diversion). Sublocade monthly LAI removes daily decision. Initiation requires patient in moderate withdrawal (COWS ≥12) — too early triggers precipitated withdrawal.
Partial agonism means buprenorphine provides enough mu opioid signal to prevent withdrawal and reduce craving, but with a ceiling effect — beyond a certain dose, more buprenorphine doesn't produce more opioid effect or more respiratory depression. The ceiling makes buprenorphine substantially safer than full agonists in overdose. Patients can take their daily dose without producing reinforcing euphoria; combined with the receptor occupancy, additional illicit opioid use produces little additional effect.
Buprenorphine treats opioid use disorder through partial mu-opioid agonism — enough to suppress withdrawal and craving, with a ceiling that limits overdose risk.
Mechanism note: Buprenorphine's partial agonism — efficacy with a safety ceiling — makes it the office-based, lower-overdose-risk OUD treatment; the key induction caveat is avoiding precipitated withdrawal.
Outpatient initiation is the major practical advantage over methadone. Buprenorphine can be prescribed in office-based practice by any provider with a DEA registration since the X-waiver elimination — no specialized opioid treatment program required. The barrier to access is dramatically lower than methadone, where federal regulations restrict dispensing to certified clinics.
- Cost
- Suboxone generic films ~$200-400/month. buprenorphine mono (generic) ~$80-200/month. Sublocade LAI ~$1,500-2,000/month.
- Generic status
- Sublingual generic for years. Sublocade brand-only.
- Formulary typical
- Sublingual: Tier 2. Sublocade: specialty tier, often covered for OUD indication.
- Access friction
- X-waiver elimination (2023) substantially eased prescribing — any DEA-registered prescriber can now prescribe. PDMP review still required. Sublocade requires REMS but reduced infrastructure vs olanzapine LAI.
Prescriber tip: For OUD, buprenorphine is now substantially more accessible than before X-waiver elimination. Suboxone (with naloxone) is the standard outpatient form. Sublocade for adherence-limited patients; Indivior patient support helps with insurance navigation.
Initiation timing is the central technical concern. The patient must be in moderate withdrawal — typically COWS (Clinical Opiate Withdrawal Scale) ≥ 12 — before the first dose. Buprenorphine has high mu receptor affinity and displaces other opioids; given too early, it precipitates severe withdrawal. The wait varies: 12-24 hours from last short-acting opioid (heroin, hydrocodone, oxycodone). Longer for methadone. Patient education and timing planning are essential. Modern "micro-induction" protocols allow lower-dose initiation overlapping with continued opioid use for patients who can't tolerate withdrawal waiting.
Suboxone — buprenorphine plus naloxone — is the standard outpatient form. The naloxone is bioavailable only if injected; it precipitates withdrawal if the tablet is misused for injection, which is the abuse-deterrent design. Taken sublingually as prescribed, only the buprenorphine has clinical effect.
Sublocade is the monthly subcutaneous LAI — buprenorphine depot providing steady plasma levels for a month. For adherence-limited patients, this removes daily dosing and eliminates the daily decision-and-craving cycle. Patient stabilizes on oral first, then transitions.
For OUD, buprenorphine is the answer for most patients most of the time.